Tue, Mar 3, 2015, 7:30 AM EST - U.S. Markets open in 2 hrs.


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • gladpick gladpick Nov 13, 2012 6:02 PM Flag



    Here is what one of them said:

    "Gilead will likely be the first to market with a simple and efficacious one pill, once-daily regimen,” Michael Yee, an RBC Capital Markets analyst in San Francisco, said in a note."

    ONE pill? If the idiot analyst read the GILD report it had THREE different drugs and not one pill. And these people get paid for the crap they spew?.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • [Over the weekend Gilead presented results from its combination of sofosbuvir and daclatasvir that cured between 98 and 100 percent of patients within 12 weeks.]

      Are they assuming that DACLATASVIR belongs to GILEAD? Did Gilead buy Bristol-Myers too?
      The trial for 7977+BMS790052(=Daclatasvir) had 3 arms, and all 3 arms dosed the dual or triple (the 3rd was Riba) combos that lasted 24 weeks, not 12weeks! Where do they get the news?

      Gilead is now developing 7977+5885, and decided not to develop 7977+Daclatasvir combo.

    • and they get paid very well. no brains, but paid well. it's all a game and they control it. you just have to be lucky to be on the right side of the trade.

120.17+0.74(+0.62%)Mar 2 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
JD.com, Inc.
NASDAQMon, Mar 2, 2015 4:00 PM EST
NXP Semiconductors NV
NASDAQMon, Mar 2, 2015 4:00 PM EST